Literature DB >> 27124287

Patient-Centered Communication for Discussing Oncotype DX Testing.

Megan C Roberts1,2, Amy Bryson3, Morris Weinberger1,4, Stacie B Dusetzina1,2,5, Michaela A Dinan6,7, Katherine E Reeder-Hayes2, Stephanie B Wheeler1,2.   

Abstract

Oncotype DX testing (ODX), a tumor gene expression test, may improve breast cancer care, however, communicating results remains challenging. We identified patient-centered communication strategies/gaps for discussing ODX results. We applied a patient-centered communication framework to analyze qualitative interviews with oncologists about how they communicate about ODX with patients, using template analysis in Atlas.ti. Overall, providers discussed four patient-centered communication domains: exchanging information, assessing uncertainty, making decisions and cross-cutting themes. Providers did not report discussing emotional aspects of managing uncertainty, assessing decision-making preferences, and evaluating decisions. A patient-centered approach may be a model for communicating about tumor gene expression tests.

Entities:  

Keywords:  Breast cancer; Communication; Patient-centered communication; Qualitative methods; Tumor gene profiling

Mesh:

Substances:

Year:  2016        PMID: 27124287      PMCID: PMC4984670          DOI: 10.3109/07357907.2016.1172637

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  14 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

Authors:  Juhi Asad; Allyson F Jacobson; Alison Estabrook; Sharon Rosenbaum Smith; Susan K Boolbol; Sheldon M Feldman; Michael P Osborne; Kwadwo Boachie-Adjei; Wendy Twardzik; Paul I Tartter
Journal:  Am J Surg       Date:  2008-10       Impact factor: 2.565

Review 3.  Psychosocial aspects of breast cancer treatment.

Authors:  D Spiegel
Journal:  Semin Oncol       Date:  1997-02       Impact factor: 4.929

4.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

5.  Improving communication of breast cancer recurrence risk.

Authors:  Noel T Brewer; Alice R Richman; Jessica T DeFrank; Valerie F Reyna; Lisa A Carey
Journal:  Breast Cancer Res Treat       Date:  2011-10-01       Impact factor: 4.872

6.  Knowledge about genomic recurrence risk testing among breast cancer survivors.

Authors:  Isaac M Lipkus; Susan T Vadaparampil; Paul B Jacobsen; Cheryl A Miree
Journal:  J Cancer Educ       Date:  2011-12       Impact factor: 2.037

Review 7.  Measuring patient-centered communication in cancer care: a literature review and the development of a systematic approach.

Authors:  Lauren A McCormack; Katherine Treiman; Douglas Rupert; Pamela Williams-Piehota; Eric Nadler; Neeraj K Arora; William Lawrence; Richard L Street
Journal:  Soc Sci Med       Date:  2011-03-04       Impact factor: 4.634

8.  Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy.

Authors:  Sarah E Lillie; Noel T Brewer; Suzanne C O'Neill; Edward F Morrill; E Claire Dees; Lisa A Carey; Barbara K Rimer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-01-30       Impact factor: 4.254

Review 9.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

Review 10.  Experiences and attitudes toward risk of recurrence testing in women with breast cancer: a systematic review.

Authors:  Laura E Leggett; Diane L Lorenzetti; Tom Noseworthy; Simran Tiwana; Gail Mackean; Fiona Clement
Journal:  Breast Cancer Res Treat       Date:  2014-03-05       Impact factor: 4.872

View more
  2 in total

1.  Benefits of introduction of Oncotype DX® testing.

Authors:  N Green; A Al-Allak; C Fowler
Journal:  Ann R Coll Surg Engl       Date:  2018-10-16       Impact factor: 1.891

2.  Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.

Authors:  Thomas M Schwedhelm; Judy R Rees; Tracy Onega; Ronnie J Zipkin; Andrew Schaefer; Maria O Celaya; Erika L Moen
Journal:  BMC Cancer       Date:  2020-09-03       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.